• 12/17/2013

    PAION AG to issue approx. 2.8 million shares at EUR 1.80 per share in capital increase with subscription rights

  • 11/26/2013

    PAION grants licence for Turkey to add to R-Pharm territory

  • 11/25/2013

    PAION AG announces positive End-of-Phase II Meeting with FDA for Remimazolam in procedural sedation

  • 11/14/2013

    PAION AG reports headline data of ONO's phase II/III trial - Remimazolam meets primary endpoint and shows good safety data

  • 10/30/2013

    PAION AG grants license to R-Pharm for Remimazolam in Russia (CIS)

  • 10/30/2013

    PAION AG announced recruitment of Ono's hepatic impairment study with Remimazolam (development codes: ONO-2745/CNS 7056) is completed

  • 10/28/2013

    PAION AG grants license to Hana Pharm for Remimazolam in South Korea

  • 09/09/2013

    PAION starts Phase II study with Remimazolam in the indication anaesthesia

  • 08/07/2013

    PAION AG reports financial results for the first half year 2013

  • 08/05/2013

    PAION AG: German regulatory authority approved Phase II study of Remimazolam in indication anaesthesia

  • 08/01/2013

    PAION's partner ONO stopped its dose finding, explorative Phase II trial in ICU sedation with Remimazolam and plans to adapt the dose regime for a new study

  • 07/02/2013

    PAION signs exclusive option agreement with Hana Pharm for Remimazolam in South Korea

  • 05/08/2013

    Recruitment of Phase II/III Study with short-acting anaesthetic/sedative Remimazolam (ONO's Development code: ONO-2745) in Japan is completed

  • 05/07/2013

    PAION receives Milestone of GBP 300,000 after Cambridge Cognition Holdings Lists on London Stock Exchange

  • 03/13/2013

    PAION AG reports financial results for the full year 2012

  • 03/06/2013

    PAION announces clinical development of short-acting anaesthetic/sedative Remimazolam in General Anaesthesia